¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Leukemia Inhibitory Factor Receptor alpha Subunit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • internalization receptor
    ³»ÀçÈ­¼ö¿ëü
  • joint receptor
    °üÀý¼ö¿ë±â
  • kinesthetic receptor
    ¿îµ¿°¨°¢¼ö¿ë±â
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ë±â
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±Ù(À°)¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • olfactory receptor
    Èİ¢¼ö¿ë±â
  • opiate receptor
    ¾ÆÆíÁ¦¼ö¿ëü
  • opioid receptor
    ¾ÆÆíÀ¯»çÁ¦¼ö¿ëü
  • postsynaptic receptor
    ½Ã³À½ºÈļö¿ëü, ¿¬Á¢Èļö¿ëü
  • prejunctional receptor
    Á¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ½Â¾Ð¼ö¿ë±â
  • paciniform receptor
    ÆÄÄ¡´ÏÇü¼ö¿ë±â
  • progesterone receptor
    ÇÁ·Î°Ô½ºÅ׷мö¿ëü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±ÙÀ°¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • olfactory receptor
    Èİ¢¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • opioid receptor
    ¾ÆÆíÀ¯»ç¹°Áú¼ö¿ëü
  • paciniform receptor
    ÆÄÄ¡´ÏÇü¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÀ°Á¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü
  • receptor potential
    °¨¼ö±âÀüÀ§, °¨¼ö±âÀü¾Ð, ¼ö¿ëüÀü¾Ð
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • platelet receptor
    Ç÷¼ÒÆÇ¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÁ¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü(äâæ³áôé»ô÷).
  • pressor receptor reflex
    ¾Ð·Â¼ö¿ëü¹Ý»ç(äâæ³áôé»ô÷ÚãÞÒ).
  • pressure receptor
    ¾Ð¼ö¿ë±â, ¾Ð·Â¼ö¿ëü(¡­áôé»ô÷).
  • progesterone receptor
    ÇÁ·Î°Ô½ºÅ×·Ð(ÇÁ·ÎÁ¦½ºÅ×·Ð)¼ö¿ëü(¡­â¥é»ô÷)
  • receptor
    ¼ö¿ë±â
  • receptor amblyopia
    ¼ö¿ë±â¾à½Ã
  • receptor assay
    ¼ö¿ëÃ¼ÃøÁ¤
  • receptor autoradiography
    ¼ö¿ëü ÀÚ±â¹æ»ç¼±ÃÔ¿µ¼ú
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blockade
    ¼ö¿ëüÂ÷´Ü
  • receptor blocking agent
    ¼ö¿ëüÂ÷´Ü<ºÀ¼â>Á¦.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • alpha-lipoproteinemia
    ¾ËÆÄ-Áö¹æ´Ü¹éÇ÷Áõ
  • alpha-naphthyl acetate esterase
    ¾ËÆÄ-³ªÇÁÆ¿¾Æ¼¼Å×ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthyl acetate esterase =ANAE
    ¾ËÆÄ¾Æ¼¼Å×ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthyl butyrate esterase
    ¾ËÆÄ-³ªÇÁÆ¿ ºÎƼ·¹ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthyl butyrate esterase =ANBE
    ¾ËÆÄºÎƼ·¹ÀÌÆ®¿¡½ºÅ×¶óÁ¦
  • alpha-naphthylamine
    ¾ËÆÄ-³ªÇÁÆ¿¾Æ¹Î
  • alpha-sympathomimetic agent
    ¾ËÆÄ±³°¨½Å°æÀ¯»çÀÛ¿ëÁ¦
  • alpha-thalassemia trait
    ¾ËÆÄ-Å»¶ó¼¼¹Ì¾Æ ¼ÒÀÎ
  • alpha/beta (¥á/¥â) ratio
    ¥á/¥â ºñ
  • angle alpha
    ¾ËÆÄ°¢
  • chain, alpha (¥á)
    ¾ËÆÄ»ç½½, ¾ËÆÄ¼â
  • cowpea(alpha-borne) mosaic virus
    Ä«¿ìÇÇ ¸ðÀÚÀÌÅ©¹ÙÀÌ·¯½º
  • galactosidase, alpha-galactosidase a, deficiency
    #NAME?
  • glucosidase, alpha -1,4-glucosidase
    -1,4-±Û·çÄڽõ¥À̽º
  • glucosidase, alpha-glucosidase(acid maltase)
    -±Û·çÄڽõ¥À̽º, -glucosidase
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • citrovorum factor
    "½ÃÆ®·Îº¸·ë ÀÎÀÚ,"
  • clearance factor
    ûÁ¤ÀÎÀÚ(ôèïäì×í­)
  • clot-promoting factor
    ÀÀ±«ÃËÁøÀÎÀÚ(ëêÎÕõµòäì×í­)
  • Col factor
    Col ÀÎÀÚ(ì×í­)
  • colicin factor
    Äݸ®½Å ÀÎÀÚ(ì×í­)
  • colicinogenic factor
    Äݸ®½Å »ý¼ºÀÎÀÚ(ßæà÷ì×í­)
  • colony-stimulating factor
    ÄݷδÏÀÚ±Ø ÀÎÀÚ(í©Ð½ì×í­)
  • contact factor
    "Á¢ÃËÀÎÀÚ(ïÈõºì×í­), (ÔÒ) Hageman factor"
  • conversion factor
    ÀüȯÀÎÀÚ(ï®üµì×í­)
  • cord factor
    ÄÚµå ÀÎÀÚ(ì×í­)
  • coupling factor
    ¦Áþ±â ÀÎÀÚ(ì×í­)
  • decay factor
    "ºØ±« ÀÎÀÚ(ÝÚÎÕì×í­), (ÔÒ) decay constant"
  • diffusing factor
    "È®»êÀÎÀÚ(üªß¤ì×í­), (ÔÒ) hyaluronidase"
  • dissociation factor
    ÇØ¸®ÀÎÀÚ(ú°×îì×í­)
  • egg white injury factor
    ÈØÀÚ ¼Õ»óÀÎÀÚ (áßß¿ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
SRIF Somatotropin Release-Inhibitory Factor
  = Somatostatin
CIF cloning inhibitory factor
CLIF cloning inhibitory factor; Crithidia luciliae immunofluorescence
CSIF cytokine synthesis inhibitory factor
GIFB growth hormone inhibitory factor, brain
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
TCR alpha/beta T cell receptor alpha/beta
alpha 1B-AR alpha 1B adrenergic receptor
alpha 2MR alpha 2 macroglobulin receptor
alpha 2AAR alpha 2-adrenergic receptor
TR alpha thyroid hormone receptor alpha
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
    1. ¼¼Æ÷Áú ³» ¶Ç´Â ¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇÏ´Â ºÐÀÚ ±¸Á¶·Î¼­
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • receptor blocking agent
    ¼ö¿ëü Â÷´ÜÁ¦
  • receptor complex
    ¼ö¿ëü º¹ÇÕü, ¼ö¿ë±â º¹ÇÕü
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±« È¿¼Ò
    ¼ö¿ëü¸¦ ÆÄ±«ÇÏ¿© ÀûÇ÷±¸ÀÇ ¹ÙÀÌ·¯½º ¿ëÇ÷¿¡ ´ëÇÑ °¨¼ö¼ºÀ» ÀÒ¾î¹ö¸®°Ô ÇÏ´Â È¿¼Ò.
  • receptor potential
    ¼ö¿ë±â ÀüÀ§
    ÀÏÁ¤ÇÑ ¹°¸®È­ÇÐÀû Àڱؿ¡ ´ëÇÏ¿© ½Å°æ ´ÜÀ§ ¼ö¿ëü¿¡¼­ ¹ß»ýÇÏ´Â Å»ºÐ±Ø.
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
  • receptor theory
    ¼ö¿ë±â ÀÌ·Ð
    Ç×ü »ý¼º ¼¼Æ÷ÀÇ Ç¥¸é¿¡´Â ƯÁ¤ Ç×ü¿¡ »óÀÀÇÏ´Â Ç׿øÀÌ °áÇÕÇ϶ó ¼ö¿ëü°¡ Á¸ÀçÇÏ¸ç ±× ¼ö¿ëüÀÇ ±¸Á¶´Â Ç×üÀÇ ±¸Á¶¿Í °°´Ù´Â ÀÌ·Ð.
  • specific membrane receptor
    ƯÁ¤ ¸· ¼ö¿ë±â
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific receptor
    ƯÀÌ ¼ö¿ëü, ƯÀÌ ¼ö¿ë±â
  • stretch receptor
    ½ÅÀå ¼ö¿ë±â
  • tactile receptor
    Ã˰¢ ¼ö¿ë±â
    Ã˰¢À» ¼ö¿ëÇÒ ¼ö ÀÖ°Ô ¸Å°³ÇØÁÖ´Â Á¶Á÷.
  • tension receptor
    Àå·Â ¼ö¿ë±â
  • Vasopressor receptor
    Ç÷°ü ¼öÃà ¼ö¿ëü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
metabotropic receptor A type of receptor that is linked to intracellular production of 1,2-diacylglycerol and inositol 1,4,5-trisphosphate.
Origin: metabolism + G. Trope, turning, inclination, + -ic
(05 Mar 2000)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
PL7a receptor-tyrosine kinase <enzyme> A member of the eph receptor tyrosine kinase subfamily; shows 80% identity with myk-1; genbank l43622
Registry number: EC 2.7.1.-
Synonym: pl7a protein
(26 Jun 1999)
Con A receptor <biochemistry> A common misuse of the term receptor. Con A binds to the mannose residues of many different glycoproteins and glycolipids and the binding is therefore not to a specific site.
It could be argued that the receptor is the Con A and cells have Con A ligands on their surfaces: certainly this would be less confusing.
(05 Jan 1998)
muscarinic acetylcholine receptor Distinct from the nicotinic ACh receptor in having no intrinsic ion channel, the receptor is formed from one protein chain with 7 transmembrane regions. The receptors produce their effect via activation of GTP-binding proteins.
(18 Nov 1997)
muscarinic receptor kinase <enzyme> Phosphorylates muscarinic acetylcholine receptors and beta-adrenergic receptors
Registry number: EC 2.7.-
Synonym: muscarinic acetylcholine receptor kinase, machr kinase
(26 Jun 1999)
cyclic AMP receptor protein A transcriptional regulator in prokaryotes which, when activated by binding cyclic AMP, acts at several promoters. Cyclic AMP receptor protein was originally identified as a catabolite gene activator protein. It was subsequently shown to regulate several functions unrelated to catabolism, and to be both a negative and a positive regulator of transcription. Cell surface cyclic AMP receptors are not included (cyclic AMP receptors), nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins, which are the regulatory subunits of cyclic AMP-dependent protein kinases.
(12 Dec 1998)
presynaptic receptor <physiology> Receptors located on presynaptic terminals at synapses.
(05 Mar 1998)
progesterone receptor assay The progesterone receptor test (PgR assay) checks the tumour for its hormone status.
(16 Dec 1997)
Xiphophorus melanoma receptor kinase <enzyme> Growth factor receptor protein with an extracellular ligand binding domain and an intracellular catalytic domain
Registry number: EC 2.7.1.-
Synonym: xmrk protein
(26 Jun 1999)
selective oestrogen-receptor modulator <pharmacology> An antioestrogen which possesses some, but not all, of the actions of oestrogen. For example, raloxifene (evista) is classified as a SERM because it prevents bone loss (like oestrogen) and lowers serum cholesterol (like oestrogen) but (unlike oestrogen) does not stimulate the endometrial lining of the uterus.
Acronym: SERM
(17 Jul 2002)
hormone receptor assay A diagnostic test to determine whether a breast cancer's growth is influenced by hormones or if it can be treated with hormones.
(09 Oct 1997)
purinergic receptor <biochemistry> Receptors that use purine nucleotides (e.g. ATP) as ligands.
(18 Nov 1997)
signal recognition particle receptor Receptor for the signal recognition particle (SRP) found in the membrane of the endoplasmic reticulum. Also called docking protein. Heterodimeric, both protomers having GTP binding capacity, though dissimilar binding sites. Not until the complex of SRP, ribosome, message and nascent polypeptide chain binds to the SRP receptor is the block to further chain elongation released and concurrently the SRP is released, leaving the ribosome attached to the endoplasmic reticulum membrane. Cotranslational transport of the polypeptide delivers it into the lumen of the ER.
(18 Nov 1997)
S-receptor kinase <enzyme> Srk - s-receptor kinase; from brassica oleracea; amino acid sequence has been determined
Registry number: EC 2.7.1.-
Synonym: srk gene product
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á